<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943267</url>
  </required_header>
  <id_info>
    <org_study_id>CEMM-APC-01</org_study_id>
    <secondary_id>MEC 08/188</secondary_id>
    <nct_id>NCT00943267</nct_id>
  </id_info>
  <brief_title>Effect of Intrapulmonary Recombinant Human Activated Protein C (APC) on Coagulation and Inflammation After Lipopolysaccharide (LPS)</brief_title>
  <official_title>Effect of Intrapulmonary Administration of Recombinant Human Activated Protein C on Local Coagulation and Inflammation After Bronchial Instillation of Lipopolysaccharide in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recombinant human Activated Protein C (rhAPC) has been shown to reduce the mortality of
      patients with severe sepsis. The biological effects of APC are pleiotropic, and can be
      roughly divided in anticoagulant and cytoprotective effects. Lung infection and inflammation
      are associated with reduced bronchoalveolar levels of endogenous APC. Recent evidence derived
      from animal studies indicates that local administration of rAPC into the lungs exerts local
      anti-inflammatory and anticoagulant effects. In this study we propose to study the potential
      of locally administered APC, within a lung subsegment, to inhibit lipopolysaccharide (LPS)
      induced lung inflammation and coagulation in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether direct intrapulmonary delivery of rhAPC can inhibit LPS-induced lung inflammation, thereby avoiding systemic APC effects</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Neutrophil responses 2. Response of alveolar macrophages 3. Activation of the cytokine and chemokine network 4. Activation of coagulation and fibrinolysis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Pneumonia</condition>
  <condition>Lipopolysaccharides</condition>
  <arm_group>
    <arm_group_label>Activated protein C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drotrecogin alpha</intervention_name>
    <description>Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0</description>
    <arm_group_label>Activated protein C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline (NaCl 0.9%)</intervention_name>
    <description>Normal saline is given intrabronchially by bronchoscopy at t=0</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endotoxin</intervention_name>
    <description>Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0</description>
    <arm_group_label>Activated protein C</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopy</intervention_name>
    <description>Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)</description>
    <arm_group_label>Activated protein C</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling is done by venapuncture at t=0 and t=6</description>
    <arm_group_label>Activated protein C</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, 18-35 years of age

          -  No clinically significant findings during physical examination and hematological and
             biochemical screening

          -  Normal spirometry and ECG

          -  Able to communicate well with the investigator and to comply with the requirements of
             the study

          -  No medication

          -  Written informed consent

          -  No smoking

        Exclusion criteria:

          -  Known diseases

          -  A history of smoking within the last six months, or regular consumption of greater
             than three units of alcohol per day

          -  Administration of any investigational drug within 30 days of study initiation

          -  Donation of blood within 60 days, or loss of greater than 400 ml of blood within 12
             weeks of study initiation

          -  History of enhanced bleeding tendency

          -  History of heparin-induced thrombocytopenia

          -  History of serious drug-related reactions, including hypersensitivity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Van der Poll, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMC/UvA Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center/ University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <last_update_submitted>March 15, 2011</last_update_submitted>
  <last_update_submitted_qc>March 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tom van der Poll MD PhD</name_title>
    <organization>Center for Experimental Molecular Medicine, AMC-UvA, Amsterdam, The Netherlands</organization>
  </responsible_party>
  <keyword>Activated Protein C</keyword>
  <keyword>Lipopolysaccharides</keyword>
  <keyword>Inflammation, Pulmonary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protein C</mesh_term>
    <mesh_term>Drotrecogin alfa activated</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

